Dowlati, Afshin

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 5,761

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine

Sarcoma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 2,824

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 2,298

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 1,415

Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials

Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., et al. (2020) · The Lancet Oncology

Sarcoma Diagnosis and TreatmentLung Cancer Treatments and Mutations

Cited by 1,028

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Research StudiesPARP inhibition in cancer therapy

Cited by 399

JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer

Ramalingam, S. S., Thara, E., Awad, M. M., Dowlati, A., Haque, B., Stinchcombe, T. E., Dy, G. K., Spigel, D. R., Lu, S., Iyer Singh, N., et al. (2022) · Cancer

Cancer Immunotherapy and BiomarkersPARP inhibition in cancer therapy

Cited by 75

Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

Beltran, H., Dowlati, A., Jain, P., Johnson, M. L., Sanborn, R. E., Thompson, J. R., Mamdani, H., Schenk, E. L., Aggarwal, R. R., Sankar, K., et al. (2024) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 32

P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC

Rudin, C., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D., Schmid, P., Heist, R., Villaflor, V., Sarkar, I., et al. (2017) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers

Cited by 14

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors.

Harvey, R. D., Falchook, G. S., Naqash, A. R., Kim, J. W., Dowlati, A., Le Bruchec, Y., Coudert, I., Ervin-Haynes, A. L., & Sommerhalder, D. (2022) · Journal of Clinical Oncology

Monoclonal and Polyclonal Antibodies ResearchSynthesis and pharmacology of benzodiazepine derivatives

Cited by 1